Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 152 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Zanubrutinib plus obinutuzumab for treating relapsed or refractory follicular lymphoma	Obinutuzumab (Gazyvaro; RO5072759; GA101; Afutuzumab) , Zanubrutinib (BGB-3111; Brukinsa)	Follicular lymphoma	Haematological Cancer and Lymphomas	2023	View \| Download
Zanubrutinib for Waldenstrom's Macroglobulinemia	Zanubrutinib (BGB-3111; Brukinsa)	Non-Hodgkin lymphoma (NHL)	Haematological Cancer and Lymphomas	2018	View \| Download
Zanubrutinib for treating marginal zone lymphoma	Zanubrutinib (BGB-3111; Brukinsa)	Marginal zone lymphoma (MZL)	Haematological Cancer and Lymphomas	2022	View \| Download
Zanubrutinib for relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma	Zanubrutinib (BGB-3111; Brukinsa)	Chronic lymphocytic leukaemia (CLL) , Small lymphocytic lymphoma (SLL)	Haematological Cancer and Lymphomas	2022	View \| Download
Zanubrutinib for previously untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma	Zanubrutinib (BGB-3111; Brukinsa)	Chronic lymphocytic leukaemia (CLL) , Small lymphocytic lymphoma (SLL)	Haematological Cancer and Lymphomas	2022	View \| Download
Zanubrutinib for previously treated mantle cell lymphoma	Zanubrutinib (BGB-3111; Brukinsa)	Mantle cell lymphoma	Haematological Cancer and Lymphomas	2023	View \| Download
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma	Zamtocabtagene autoleucel	Diffuse large B-cell lymphoma (DLBCL)	Haematological Cancer and Lymphomas	2022	View \| Download
Zamtocabtagene autoleucel for relapsed or refractory diffuse large B-cell lymphoma after at least 2 therapies	Zamtocabtagene autoleucel	Diffuse large B-cell lymphoma (DLBCL)	Haematological Cancer and Lymphomas	2022	View \| Download
Venetoclax with dexamethasone for previously treated relapsed/refractory multiple myeloma	Dexamethasone (dexamethasone sodium metasulfobenzoate) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2021	View \| Download
Venetoclax in Combination with Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukaemia – First Line	Obinutuzumab (Gazyvaro; RO5072759; GA101; Afutuzumab) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199)	Chronic lymphocytic leukaemia (CLL)	Haematological Cancer and Lymphomas	2017	View \| Download